Intramyocardial delivery of human CD133+cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells

被引:65
作者
Ma, Nan
Ladilov, Yury
Moebius, Jeannette M.
Ong, Leelee
Piechaczek, Christoph
David, Arpad
Kaminski, Alexander
Choi, Yeong-Hoon
Li, Wenzhong
Egger, Dietmar
Stamm, Christof
Steinhoff, Gustav
机构
[1] Univ Rostock, Dept Cardiac Surg, Rostock, Germany
[2] Vita34, Leipzig, Germany
关键词
cell therapy; angiogenesis; cell differentiation; stem cells;
D O I
10.1016/j.cardiores.2006.03.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The regenerative potential of endothelial and hematopoietic progenitor cells in the heart may vary according to their origin. This study was designed to compare the functional effects of CD133+ cells from human cord blood and bone marrow in a mouse model of myocardial injury. Methods: 5 x 10(5) CD133+ cells from bone marrow (BMCD133) or cord blood (UCBCD133) were injected in the necrosis border zone of NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice with left ventricular cryoinjury (CI+). Transplanted cells were tracked by immunostaining for hNuclear antigen and by PCR for hDNA. Echocardiography was used to measure contractility. Sear size, capillary density, and cardiomyocyte apoptosis were evaluated by histology. In addition, the myogenic, and endothelial differentiation capacity of BMCD133 and UCBCD133 was compared in vitro. Results: DNA was detected 4 weeks after cell injection by PCR, but hNuc+ cells were found by immunostaining only after 48 h. Capillary density in both BMCD133 and UCBCD133 cell-treated CI+ mice was higher than in control CI+ mice, but not different between BMCD133 and UCBCD133 cell-treated hearts. There were no differences in scar size and myocardial mass among BMCD133, UCBCD133 and control CI+ mice, but cardiomyocyte apoptosis was reduced by both BMCD133 and UCBCD133 cells. The post-injury deterioration of shortening fraction (46.2 +/- 1% in sham-operated mice and 41.3 +/- 0.8% in control CI+ mice) was prevented by BMCD133 cells (45.4 +/- 0.9%), but not by UCBCD133 cells (40.8 +/- 0.7%). On the other hand, both BMCD133 and UCBCD133 cells abolished post-injury mortality. In vitro, neither cultivated BMCD133 or UCBCD133 cells developed into myocytes, but both readily differentiated towards an endothelial cell phenotype. Conclusions: While both cord blood and marrow CD133+ cells have some beneficial effects on post-injury angiogenesis and survival, only marrow cells appear to improve myocardial contractility. (c) 2006 European Society of Cardiology. Published by Elsevier B.V.
引用
收藏
页码:158 / 169
页数:12
相关论文
共 41 条
[1]   Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium [J].
Agbulut, O ;
Vandervelde, S ;
Al Attar, N ;
Larghero, J ;
Ghostine, S ;
Léobon, B ;
Robidel, E ;
Borsani, P ;
Le Lorc'h, M ;
Bissery, A ;
Chomienne, C ;
Bruneval, P ;
Marolleau, JP ;
Vilquin, JT ;
Hagège, A ;
Samuel, JL ;
Menasché, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (02) :458-463
[2]   Derivation of functional endothelial progenitor cells from human umbilical cord blood mononuclear cells isolated by a novel cell filtration device [J].
Aoki, M ;
Yasutake, M ;
Murohara, T .
STEM CELLS, 2004, 22 (06) :994-1002
[3]   Expression of transcription factor Oct-4 and other embryonic genes in CD133 positive cells from human umbilical cord blood [J].
Baal, N ;
Reisinger, K ;
Jahr, H ;
Bohle, RM ;
Liang, O ;
Münstedt, K ;
Rao, CV ;
Preissner, KT ;
Zygmunt, MT .
THROMBOSIS AND HAEMOSTASIS, 2004, 92 (04) :767-775
[4]   Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes [J].
Badorff, C ;
Brandes, RP ;
Popp, R ;
Rupp, S ;
Urbich, C ;
Aicher, A ;
Fleming, I ;
Busse, R ;
Zeiher, A ;
Dimmeler, S .
CIRCULATION, 2003, 107 (07) :1024-1032
[5]   Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction - Feasibility and safety [J].
Bartunek, J ;
Vanderheyden, M ;
Vandekerckhove, B ;
Mansour, S ;
De Bruyne, B ;
De Bondt, P ;
Van Haute, I ;
Lootens, N ;
Heyndrickx, G ;
Wijns, W .
CIRCULATION, 2005, 112 (09) :I178-I183
[6]   Adult cardiac stem cells are multipotent and support myocardial regeneration [J].
Beltrami, AP ;
Barlucchi, L ;
Torella, D ;
Baker, M ;
Limana, F ;
Chimenti, S ;
Kasahara, H ;
Rota, M ;
Musso, E ;
Urbanek, K ;
Leri, A ;
Kajstura, J ;
Nadal-Ginard, B ;
Anversa, P .
CELL, 2003, 114 (06) :763-776
[7]   AC133 expression in human stem cells [J].
Bhatia, M .
LEUKEMIA, 2001, 15 (11) :1685-1688
[8]   Clinical isolation and functional characterization of cord blood CD133+hematopoietic progenitor cells [J].
Bonanno, G ;
Perillo, A ;
Rutella, S ;
de Ritis, DG ;
Mariotti, A ;
Marone, M ;
Meoni, F ;
Scambia, G ;
Leone, G ;
Mancuso, S ;
Pierelli, L .
TRANSFUSION, 2004, 44 (07) :1087-1097
[9]   CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors [J].
de Wynter, EA ;
Buck, D ;
Hart, C ;
Heywood, R ;
Coutinho, LH ;
Clayton, A ;
Rafferty, JA ;
Burt, D ;
Guenechea, G ;
Bueren, JA ;
Gagen, D ;
Fairbairn, LJ ;
Lord, BI ;
Testa, NG .
STEM CELLS, 1998, 16 (06) :387-396
[10]   Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood [J].
Eggermann, J ;
Kliche, S ;
Jarmy, G ;
Hoffmann, K ;
Mayr-Beyrle, U ;
Debatin, KM ;
Waltenberger, J ;
Beltinger, C .
CARDIOVASCULAR RESEARCH, 2003, 58 (02) :478-486